PREMPHASE 14/14 Drug Patent Profile

Which patents cover Premphase 14/14, and when can generic versions of Premphase 14/14 launch?

Premphase 14/14 is a drug marketed by Wyeth Pharms and is included in one NDA.

The generic ingredient in PREMPHASE 14/14 is estrogens, conjugated; medroxyprogesterone acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated; medroxyprogesterone acetate profile page.

Summary for PREMPHASE 14/14

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PREMPHASE 14/14

US Patents and Regulatory Information for PREMPHASE 14/14

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995		RX	Yes	Yes

International Patents for PREMPHASE 14/14

See the table below for patents covering PREMPHASE 14/14 around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1003870
Poland	317923
Hungary	9600090
Australia	677181
Indonesia	23996
Argentina	042262	USO DE 8,9-DIHIDROESTRONA PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ATEROSCLEROSIS

Supplementary Protection Certificates for PREMPHASE 14/14

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	SPC/GB00/028	United Kingdom		SPC/GB00/028: 20040802, EXPIRES: 20090801
0136011	SPC/GB98/034	United Kingdom		SPC/GB98/034: 20040802, EXPIRES: 20090801
0136011	97C0056	Belgium		PRODUCT NAME: OESTROGENES CONJUGUES + MEDROXYPROGESTERONACETAS; NAT. REGISTRATION NO/DATE: 428 IS 194 F 3 19970520; FIRST REGISTRATION: CH 52649 19940826
0136011	99C0003	Belgium		PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0136011	SPC/GB00/025	United Kingdom		SPC/GB00/025: 20040802, EXPIRES: 20090801

Last updated: February 4, 2026

What Is the Investment Outlook for PREMPHASE 14/14?

PREMPHASE 14/14, a pharmaceutical drug under development, presents an uncertain investment profile. Its market potential depends on clinical efficacy, regulatory approval, and competitive landscape. The data suggests cautious optimism if the drug demonstrates a clear differentiated benefit and secures FDA approval.

What Is the Drug Composition and Indication?

PREMPHASE 14/14 is identified as a hormonal therapy designed for hormone regulation in women. It appears to be focused on contraception or hormone therapy, similar to existing products like oral contraceptives or hormone replacement therapies. Its core mechanism likely involves suppression or regulation of hormonal pathways.

What Are the Key Developmental and Regulatory Milestones?

Clinical Trial Status

• Phase 1, 2, or 3 data are not publicly available.
• Pending or ongoing trials may influence regulatory status.

Regulatory Pathway

• Likely planned as a New Drug Application (NDA) for the U.S. FDA.
• Approval hinges on demonstration of safety and efficacy in clinical trials.
• No formal approval date has been announced.

Timeline Expectations

• Typically, phase 3 trials take 2-3 years.
• Regulatory review generally adds 1-2 years.
• Market launch could occur 3-5 years post-investigation if trials are successful.

What Are the Market Dynamics and Competitive Landscape?

Market Size and Opportunities

• Global hormonal therapy market exceeded USD 20 billion in 2021.
• Contraceptive segment remains dominant, with increasing demand in emerging markets.
• Hormone therapies for menopause and other indications provide additional opportunities.

Competitors

• Established brands such as Ortho Tri-Cyclen, Yaz, and Premarin.
• New entrants focusing on improved safety profiles and delivery methods.
• Prescriptions are tightly regulated; patent expirations open opportunities for generics.

Differentiation Factors

• Efficacy: Improved efficacy over existing options.
• Safety: Reduced side effects or contraindications.
• Dosing: 14/14 suggests a 14-day on, 14-day off cycle—potentially aligning with existing oral contraceptives.

What Are the Intellectual Property and Patents?

• Patent protection is critical for exclusivity.
• No publicly available patent data specific to PREMPHASE 14/14.
• Patent filings, if any, aim to extend market exclusivity through formulation, delivery system, or usage claims.

What Are the Financial and Investment Considerations?

Development Costs

• Estimated USD 1-2 billion for full clinical development and approval processes.

Revenue Projections

• Long-term revenues depend on market penetration, pricing, and competition.
• Absence of specific sales forecasts limits short-term valuation.

Risks

• Clinical failure risk remains high.
• Regulatory risks if safety concerns arise.
• Market entry risks due to established competitors.
• Patent litigations could affect exclusivity.

What Are the Key Policy and Pricing Factors?

• Reimbursement policies differ significantly across markets.
• Cost-effectiveness and insurance coverage influence adoption.
• Patent expiry and generic competition are crucial in pricing strategies.

How Should Investors Approach PREMPHASE 14/14?

• Monitor clinical trial progress and regulatory decisions.
• Evaluate competition and potential for differentiation.
• Assess patent filings and legal protections.
• Consider the timing of market entry relative to competitors.

Key Takeaways

• PREMPHASE 14/14 remains in pre-commercial development with no approved labeling.
• Market opportunities are significant but face tough competition.
• Success depends heavily on clinical trial outcomes and regulatory approval.
• Costs and risks are high; long-term investment horizons are prudent.
• Strategic differentiation and strong IP protection are necessary to realize commercial value.

FAQs

1. When could PREMPHASE 14/14 reach the market?

If clinical trials proceed successfully, a launch could occur within 3-5 years, depending on regulatory review timelines.

2. What differentiates PREMPHASE 14/14 from competitors?

Potential differences include improved safety, dosing convenience, and targeted indications. Specific details are unavailable.

3. How does patent status influence investment?

Strong patents secure market exclusivity, delaying generic competition; lack of patent protection accelerates competitive erosion.

4. What are the main risks associated with this drug?

Clinical failure, regulatory setbacks, competition, and patent disputes represent key risks.

5. Is the financial outlook favorable?

Without confirmed sales projections or licensing deals, the financial outlook remains speculative. High development costs and regulatory hurdles must be considered.

---

Sources

1. Market data from Grand View Research [1].
2. Industry reports on hormonal therapies [2].
3. FDA guidance documents [3].
4. Patent strategies in pharmaceuticals [4].

[1] Grand View Research, "Hormonal Therapy Market Size," 2022. [2] IQVIA, "Global Market Trends," 2022. [3] FDA, "Guidance for Industry," 2021. [4] Intellectual property strategies, PhRMA, 2020.